FY2024 Earnings Forecast for CARM Issued By HC Wainwright

Carisma Therapeutics, Inc. (NASDAQ:CARM) – Research analysts at HC Wainwright boosted their FY2024 earnings per share estimates for Carisma Therapeutics in a research note issued to investors on Monday, November 25th. HC Wainwright analyst M. Kapoor now expects that the company will post earnings per share of ($1.32) for the year, up from their previous estimate of ($1.33). HC Wainwright has a “Buy” rating and a $5.00 price objective on the stock. The consensus estimate for Carisma Therapeutics’ current full-year earnings is ($1.33) per share. HC Wainwright also issued estimates for Carisma Therapeutics’ Q1 2025 earnings at ($0.28) EPS, Q2 2025 earnings at ($0.27) EPS, Q3 2025 earnings at ($0.22) EPS and FY2025 earnings at ($1.00) EPS.

Separately, EF Hutton Acquisition Co. I raised Carisma Therapeutics to a “strong-buy” rating in a research report on Wednesday, October 30th.

Carisma Therapeutics Price Performance

Carisma Therapeutics stock opened at $0.85 on Wednesday. Carisma Therapeutics has a 1 year low of $0.80 and a 1 year high of $3.16. The firm has a 50 day moving average price of $0.97 and a 200 day moving average price of $1.10. The company has a market cap of $35.49 million, a price-to-earnings ratio of -0.54 and a beta of 1.49. The company has a debt-to-equity ratio of 1.39, a quick ratio of 3.23 and a current ratio of 3.23.

Carisma Therapeutics (NASDAQ:CARM) last released its earnings results on Thursday, November 7th. The company reported ($0.31) EPS for the quarter, hitting the consensus estimate of ($0.31). Carisma Therapeutics had a negative net margin of 314.78% and a negative return on equity of 957.20%. The firm had revenue of $3.39 million during the quarter.

Institutional Trading of Carisma Therapeutics

Several hedge funds have recently made changes to their positions in CARM. Barclays PLC raised its holdings in shares of Carisma Therapeutics by 3,661,933.3% in the 3rd quarter. Barclays PLC now owns 549,305 shares of the company’s stock worth $539,000 after purchasing an additional 549,290 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Carisma Therapeutics during the 2nd quarter worth about $40,000. Wexford Capital LP boosted its holdings in Carisma Therapeutics by 75.5% in the 3rd quarter. Wexford Capital LP now owns 34,861 shares of the company’s stock valued at $34,000 after purchasing an additional 15,000 shares during the period. Finally, Vanguard Group Inc. boosted its position in shares of Carisma Therapeutics by 0.7% during the 1st quarter. Vanguard Group Inc. now owns 1,579,961 shares of the company’s stock valued at $3,587,000 after acquiring an additional 11,200 shares in the last quarter. Institutional investors own 44.27% of the company’s stock.

Carisma Therapeutics Company Profile

Carisma Therapeutics, Inc, a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others.